(Bloomberg) -- President Donald Trump has spent the past year touting lower drug prices he's negotiated with pharmaceutical companies. The world's biggest drugmakers aren't yet feeling the pain. Most Read from Bloomberg Google Erases a Record $500 Billion as AI Eats Into Sales Marvell Is Close to Megadeal for Laser Maker Lumentum in AI Push Indonesia's Wealth Fund CIO Owns Stake in Sanctioned Brokerage Joe Rogan's Microphone Goes Quieter on Trump Three of the largest US drugmakers reported record quarterly revenue on Thursday. Eli Lilly & Co., Merck & Co. and Bristol Myers Squibb Co. all raised their forecasts for the year. They cited strong demand for new treatments and established blockbusters like Lilly's weight-loss powerhouse Zepbound.
Головну думку ми показуємо публічно. Створіть безкоштовний акаунт, щоб читати повну статтю, зберігати її, обговорювати та поєднувати з ринковим і OSINT-контекстом.